Table 1.
Therapeutic response of targeted therapy in mutant cancers.
| Drugs | Sensitivity | Target mutations | Cancer types | Reference |
|---|---|---|---|---|
| Gefitinib | + | EGFR-L858R | Lung cancer | (7) |
| Erlotinib | + | EGFR-L858R | Lung cancer | (7) |
| Gefitinib | – | EGFR-T789M | Lung cancer | (8) |
| Osimertinib | + | EGFR-T790M | Lung cancer | (9) |
| Osimertinib | – | EGFR-L718Q | Lung cancer | (10) |
| Trastuzumab | – | HER2-A859T, -G776L | Lung cancer | (11) |
| Afatinib | + | HER2-p.Tyr772_Ala775dup | Lung cancer | (12) |
| Neratinib | – | HER2-T798I, -L869R | Breast cancer | (13) |
| Lapatinib | – | HER2-T798M | Breast cancer | (14) |
| Trastuzumab | – | HER2-T798M | Breast cancer | (14) |
| Neratinib | + | HER2-S310, -L755, -V777, -G778_P780dup, and -Y772_A775dup | Breast, cervical and biliary cancers | (15) |
| Crizotinib | – | ALK-C1156Y, -L1196M | Lung cancer | (16, 17) |
| Lorlatinib | – | ALK-L1198F | Lung cancer | (18) |
| 2,4-Pyrimidinediamine derivative | – | EML4-ALK-C1156Y, -L1196M | Lung cancer | (19) |
| TAE684 | – | EML4-ALK-L1152R | Lung cancer | (20) |
| Dabrafenib | + | BRAF-V600E | Melanoma | (5) |